Status of immune‐based therapies in HIV infection and AIDS

Clinical & Experimental Immunology

Volumn 88, Issue 1, 1992, Pages 1-5

  FAHEY, J L ^a   SCHOOLEY, R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

antibodies; cytokines; growth factors; HIV; immune modulators; vaccines

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; DIETHYLDITHIOCARBAMIC ACID; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 2; METHISOPRINOL; OKT 4; VACCINE; VIRUS ANTIBODY; VIRUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOCYTOPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CYTOKINES; GROWTH SUBSTANCES; HIV INFECTIONS; HUMAN; IMMUNOTHERAPY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026547686     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1992.tb03029.x     Document Type: Review

References (21)

1. Safety and effects of interleukin–2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus
2. Combination interleukin‐2 and zidovudine therapy of HIV‐1 infected patients
3. Augmentation of anti‐HIV ADCC with interleukin 2
4. Combined zidovudine and interferon‐alpha therapy in patients with Kaposi's sarcoma in AIDS
5. Interferon‐alpha in patients with asymptomatic HIV infection. Randomized placebo‐controlled trial
6. Alpha interferon in the treatment of AIDS‐related Kaposi's sarcoma
7. Interferon‐alpha with zidovudine: safety, tolerance and clinical and virologic effects in Kaposi's sarcoma associated with AIDS
8. Beta‐interferon therapy in patients with poor–prognosis Kaposi's sarcoma related to AIDS
9. Uses of recombinant interferons and hematologic growth factors in patients with HIV infection
10. Effective therapy of the LP‐BM5 murine retrovirus‐induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate
11. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized double‐blind placebo‐controlled multicenter study
12. The efficacy of inosine panobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus
13. Recombinant soluble CD4 therapy in patients with AIDS and ARC: a phase I–II escalating dose trial
14. Primary HIV‐1 isolates are relatively resistant to neutralization by recombinant soluble CD4 (sCD4)
15. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type‐1 isolates
16. Phase I study of rCD4–lgG administered by continuous intravenous (IV) infusion to patients with AIDS or ARC
17. Recombinant interleukin‐2 as an adjuvant for vaccine‐induced protection: immunization of guinea pigs with subunit HSV vaccines
18. HIV vaccine therapy: phase 1 safety and immunogenicity evaluation of post infection immune modification by active immunization with recombinant gp160
19. The whole virus approach to immunization
20. Immunization of HIV infected individuals with inactivated HIV immunogen: Significance of HIV‐specific cell‐mediated immune response